RxDoctor Payments DataLook up a doctor →

Richard Michal, MD

Family Medicine · Rocky Mount, NCNPI 1558413757

Payments from drug & device makers

$96,878in general payments, 2019–2025

Across 813 payments — averaging $119.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$87K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Esperion Therapeutics, Inc.$1K
  • AbbVie$756
  • Lilly USA, LLC$723
  • plus $4K from 35 others

What the payments were for

  • Consulting fees$1,8232%
  • Speaking & faculty fees$79,70082%
  • Travel & lodging$1,0061%
  • Food & beverage$14,09315%
  • Education$2570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$96,878 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$72,267
Medicare patients
111
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab259$225,149
JardianceEmpagliflozin176$162,038
EliquisApixaban95$64,062
RybelsusSemaglutide35$60,522
OzempicSemaglutide42$49,823
FarxigaDapagliflozin Propanediol34$32,196
NexlizetBempedoic Acid/Ezetimibe40$30,457
VraylarCariprazine Hcl13$18,909
Repatha PushtronexEvolocumab24$16,780
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,554
Repatha SyringeEvolocumab11$10,008
EntrestoSacubitril/Valsartan12$7,692
Effexor XrVenlafaxine Hcl12$7,531
NexletolBempedoic Acid20$7,493
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$7,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$593$162,038176 claims
Novo NordiskRybelsus, Ozempic$1,385$110,34577 claims
PfizerEliquis, Effexor Xr$417$71,594107 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$1,005$37,95160 claims
AstraZenecaFarxiga$1,883$32,19634 claims
AbbVieVraylar, Synthroid$756$24,99384 claims
GSKTrelegy Ellipta$482$11,55414 claims
NovartisEntresto$181$7,69212 claims
Astellas Pharma US IncMyrbetriq$13$6,72316 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$70$66770 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →